Articles

Articles
PROMINENT, REDUCE-IT, and STRENGTH Investigators. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
Ridker PM, Bhatt DL, Pradhan AD, et al.
Journal:
Lancet

First published: March 6, 2023 DOI: 10.1016/S0140-6736(23)00215-5
View
- Share
Articles
Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial
Ballantyne CM, Banka P, Mendez G, et al.
Journal:
J Am Coll Cardiol

First published: March 6, 2023 DOI: 10.1016/j.jacc.2023.02.018
View
- Share
Articles
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
Schwartz GG, Szarek M, Bhatt DL, et al.
Journal:
Eur Heart J

First published: March 5, 2023 DOI: 10.1093/eurheartj/ehad144
View
- Share
Articles
CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Nissen SE, Lincoff AM, Brennan D, et al.
Journal:
N Engl J Med

First published: March 4, 2023 DOI: 10.1056/NEJMoa2215024
View
- Share
Articles
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial
Zelniker TA, Wiviott SD, Mosenzon O, et al.
Journal:
JAMA Cardiol

First published: March 1, 2023 DOI: 10.1001/jamacardio.2023.0019
View
- Share
Articles
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study
Arnold SV, de Lemos JA, Zheng L, et al.
Journal:
Diabetes Obes Metab

First published: February 27, 2023 DOI: 10.1111/dom.15032
View
- Share
Articles
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the national lipid association and the American society for preventive cardiology
Virani SS, Aspry K, Dixon DL, et al.
Journal:
J Clin Lipidol

First published: February 27, 2023 DOI: 10.1016/j.jacl.2023.02.003
View
- Share
Articles
Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative
Catapano AL, De Caterina R, Jukema JW, et al.
Journal:
Clin Cardiol

First published: February 17, 2023 DOI: 10.1002/clc.23988
View
- Share
Articles
Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial
Ridker PM, Lei L, Ray KK, et al.
Journal:
J Clin Lipidol

First published: February 14, 2023 DOI: 10.1016/j.jacl.2023.02.002
View
- Share
Articles
Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease
Dron JS, Patel AP, Zhang Y, et al.
Journal:
JAMA Cardiol

First published: February 1, 2023 DOI: 10.1001/jamacardio.2022.5271
View
- Share
Articles
US Trends in Cholesterol Screening, Lipid Levels, and Lipid-Lowering Medication Use in US Adults, 1999 to 2018
Gao Y, Shah LM, Ding J, et al.
Journal:
J Am Heart Assoc

First published: January 10, 2023 DOI: 10.1161/JAHA.122.028205
View
- Share
Articles
Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease
Krishnaraj A, Bakbak E, Teoh H, et al.
Journal:
Med (N Y)

First published: January 10, 2023 DOI: 10.1016/j.medj.2022.12.008
View
- Share

1 2 3 … 20

Articles

Articles

PROMINENT, REDUCE-IT, and STRENGTH Investigators. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials

Ridker PM, Bhatt DL, Pradhan AD, et al.

Articles

Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial

Ballantyne CM, Banka P, Mendez G, et al.

Articles

Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Schwartz GG, Szarek M, Bhatt DL, et al.

Articles

CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Nissen SE, Lincoff AM, Brennan D, et al.

Articles

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial

Zelniker TA, Wiviott SD, Mosenzon O, et al.

Articles

Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study

Arnold SV, de Lemos JA, Zheng L, et al.

Articles

The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the national lipid association and the American society for preventive cardiology

Virani SS, Aspry K, Dixon DL, et al.

Articles

Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative

Catapano AL, De Caterina R, Jukema JW, et al.

Articles

Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial

Ridker PM, Lei L, Ray KK, et al.

Articles

Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease

Dron JS, Patel AP, Zhang Y, et al.

Articles

US Trends in Cholesterol Screening, Lipid Levels, and Lipid-Lowering Medication Use in US Adults, 1999 to 2018

Gao Y, Shah LM, Ding J, et al.

Articles

Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease

Krishnaraj A, Bakbak E, Teoh H, et al.

Articles

PROMINENT, REDUCE-IT, and STRENGTH Investigators. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials

Ridker PM, Bhatt DL, Pradhan AD, et al.

Share

Articles

Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial

Ballantyne CM, Banka P, Mendez G, et al.

Share

Articles

Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Schwartz GG, Szarek M, Bhatt DL, et al.

Share

Articles

CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Nissen SE, Lincoff AM, Brennan D, et al.

Share

Articles

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial

Zelniker TA, Wiviott SD, Mosenzon O, et al.

Share

Articles

Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study

Arnold SV, de Lemos JA, Zheng L, et al.

Share

Articles

The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the national lipid association and the American society for preventive cardiology

Virani SS, Aspry K, Dixon DL, et al.

Share

Articles

Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative

Catapano AL, De Caterina R, Jukema JW, et al.

Share

Articles

Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial

Ridker PM, Lei L, Ray KK, et al.

Share

Articles

Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease

Dron JS, Patel AP, Zhang Y, et al.

Share

Articles

US Trends in Cholesterol Screening, Lipid Levels, and Lipid-Lowering Medication Use in US Adults, 1999 to 2018

Gao Y, Shah LM, Ding J, et al.

Share

Articles

Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease

Krishnaraj A, Bakbak E, Teoh H, et al.

Share